nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosentan—CYP2C9—Capecitabine—esophageal cancer	0.0431	0.665	CbGbCtD
Bosentan—CYP2C9—Cisplatin—esophageal cancer	0.0217	0.335	CbGbCtD
Bosentan—Acute coronary syndrome—Cisplatin—esophageal cancer	0.0019	0.00335	CcSEcCtD
Bosentan—Renal failure—Cisplatin—esophageal cancer	0.00189	0.00334	CcSEcCtD
Bosentan—Myocardial infarction—Cisplatin—esophageal cancer	0.00189	0.00333	CcSEcCtD
Bosentan—Cardiac failure—Capecitabine—esophageal cancer	0.00189	0.00333	CcSEcCtD
Bosentan—Cerebrovascular accident—Capecitabine—esophageal cancer	0.00188	0.00332	CcSEcCtD
Bosentan—Lethargy—Capecitabine—esophageal cancer	0.00188	0.00332	CcSEcCtD
Bosentan—Stomatitis—Cisplatin—esophageal cancer	0.00188	0.00332	CcSEcCtD
Bosentan—Conjunctivitis—Cisplatin—esophageal cancer	0.00187	0.00331	CcSEcCtD
Bosentan—Hyponatraemia—Capecitabine—esophageal cancer	0.00185	0.00327	CcSEcCtD
Bosentan—Cystitis noninfective—Methotrexate—esophageal cancer	0.00184	0.00326	CcSEcCtD
Bosentan—Pain in extremity—Capecitabine—esophageal cancer	0.00184	0.00325	CcSEcCtD
Bosentan—Disturbance in sexual arousal—Capecitabine—esophageal cancer	0.00183	0.00323	CcSEcCtD
Bosentan—Cystitis—Methotrexate—esophageal cancer	0.00182	0.00322	CcSEcCtD
Bosentan—Hepatobiliary disease—Cisplatin—esophageal cancer	0.00182	0.00322	CcSEcCtD
Bosentan—Bradycardia—Cisplatin—esophageal cancer	0.00176	0.00311	CcSEcCtD
Bosentan—Irritability—Capecitabine—esophageal cancer	0.00176	0.00311	CcSEcCtD
Bosentan—Cardiac arrest—Capecitabine—esophageal cancer	0.00175	0.00309	CcSEcCtD
Bosentan—Mood swings—Capecitabine—esophageal cancer	0.00174	0.00308	CcSEcCtD
Bosentan—Dehydration—Capecitabine—esophageal cancer	0.00171	0.00303	CcSEcCtD
Bosentan—Ecchymosis—Methotrexate—esophageal cancer	0.00171	0.00302	CcSEcCtD
Bosentan—Bladder pain—Methotrexate—esophageal cancer	0.00171	0.00302	CcSEcCtD
Bosentan—Mouth ulceration—Methotrexate—esophageal cancer	0.00171	0.00302	CcSEcCtD
Bosentan—Urinary tract disorder—Cisplatin—esophageal cancer	0.00171	0.00302	CcSEcCtD
Bosentan—Liver function test abnormal—Capecitabine—esophageal cancer	0.0017	0.003	CcSEcCtD
Bosentan—Urethral disorder—Cisplatin—esophageal cancer	0.00169	0.00299	CcSEcCtD
Bosentan—Dry skin—Capecitabine—esophageal cancer	0.00169	0.00298	CcSEcCtD
Bosentan—Orthostatic hypotension—Capecitabine—esophageal cancer	0.00168	0.00297	CcSEcCtD
Bosentan—Abdominal pain upper—Capecitabine—esophageal cancer	0.00168	0.00297	CcSEcCtD
Bosentan—Pulmonary oedema—Methotrexate—esophageal cancer	0.00168	0.00297	CcSEcCtD
Bosentan—Hypokalaemia—Capecitabine—esophageal cancer	0.00168	0.00296	CcSEcCtD
Bosentan—Nasopharyngitis—Capecitabine—esophageal cancer	0.00165	0.00291	CcSEcCtD
Bosentan—Eye disorder—Cisplatin—esophageal cancer	0.00162	0.00285	CcSEcCtD
Bosentan—Tinnitus—Cisplatin—esophageal cancer	0.00161	0.00285	CcSEcCtD
Bosentan—Flushing—Cisplatin—esophageal cancer	0.0016	0.00283	CcSEcCtD
Bosentan—Cardiac disorder—Cisplatin—esophageal cancer	0.0016	0.00283	CcSEcCtD
Bosentan—Abdominal distension—Capecitabine—esophageal cancer	0.0016	0.00283	CcSEcCtD
Bosentan—Asthma—Capecitabine—esophageal cancer	0.00159	0.00281	CcSEcCtD
Bosentan—Influenza—Capecitabine—esophageal cancer	0.00159	0.00281	CcSEcCtD
Bosentan—Bronchospasm—Capecitabine—esophageal cancer	0.00157	0.00277	CcSEcCtD
Bosentan—Immune system disorder—Cisplatin—esophageal cancer	0.00156	0.00276	CcSEcCtD
Bosentan—Mediastinal disorder—Cisplatin—esophageal cancer	0.00156	0.00275	CcSEcCtD
Bosentan—Angina pectoris—Capecitabine—esophageal cancer	0.00155	0.00274	CcSEcCtD
Bosentan—Sweating increased—Capecitabine—esophageal cancer	0.00155	0.00274	CcSEcCtD
Bosentan—Bronchitis—Capecitabine—esophageal cancer	0.00153	0.0027	CcSEcCtD
Bosentan—Hepatic failure—Methotrexate—esophageal cancer	0.00153	0.0027	CcSEcCtD
Bosentan—Malnutrition—Cisplatin—esophageal cancer	0.0015	0.00266	CcSEcCtD
Bosentan—Erythema—Cisplatin—esophageal cancer	0.0015	0.00266	CcSEcCtD
Bosentan—Neutropenia—Capecitabine—esophageal cancer	0.00149	0.00263	CcSEcCtD
Bosentan—Dysuria—Capecitabine—esophageal cancer	0.00149	0.00263	CcSEcCtD
Bosentan—Flatulence—Cisplatin—esophageal cancer	0.00148	0.00262	CcSEcCtD
Bosentan—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.00148	0.00261	CcSEcCtD
Bosentan—Weight increased—Capecitabine—esophageal cancer	0.00145	0.00256	CcSEcCtD
Bosentan—Muscle spasms—Cisplatin—esophageal cancer	0.00145	0.00256	CcSEcCtD
Bosentan—Weight decreased—Capecitabine—esophageal cancer	0.00144	0.00254	CcSEcCtD
Bosentan—Hyperglycaemia—Capecitabine—esophageal cancer	0.00144	0.00254	CcSEcCtD
Bosentan—Pneumonia—Capecitabine—esophageal cancer	0.00143	0.00252	CcSEcCtD
Bosentan—Infestation NOS—Capecitabine—esophageal cancer	0.00142	0.00251	CcSEcCtD
Bosentan—Infestation—Capecitabine—esophageal cancer	0.00142	0.00251	CcSEcCtD
Bosentan—Vision blurred—Cisplatin—esophageal cancer	0.00142	0.00251	CcSEcCtD
Bosentan—Tremor—Cisplatin—esophageal cancer	0.00141	0.00249	CcSEcCtD
Bosentan—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	0.00141	0.00249	CcSEcCtD
Bosentan—Acute coronary syndrome—Capecitabine—esophageal cancer	0.0014	0.00247	CcSEcCtD
Bosentan—Lethargy—Methotrexate—esophageal cancer	0.0014	0.00247	CcSEcCtD
Bosentan—Cerebrovascular accident—Methotrexate—esophageal cancer	0.0014	0.00247	CcSEcCtD
Bosentan—Renal failure—Capecitabine—esophageal cancer	0.0014	0.00246	CcSEcCtD
Bosentan—Myocardial infarction—Capecitabine—esophageal cancer	0.00139	0.00246	CcSEcCtD
Bosentan—Anaemia—Cisplatin—esophageal cancer	0.00139	0.00246	CcSEcCtD
Bosentan—Stomatitis—Capecitabine—esophageal cancer	0.00138	0.00244	CcSEcCtD
Bosentan—Jaundice—Capecitabine—esophageal cancer	0.00138	0.00244	CcSEcCtD
Bosentan—Conjunctivitis—Capecitabine—esophageal cancer	0.00138	0.00244	CcSEcCtD
Bosentan—Urinary tract infection—Capecitabine—esophageal cancer	0.00138	0.00244	CcSEcCtD
Bosentan—Haematuria—Capecitabine—esophageal cancer	0.00135	0.00239	CcSEcCtD
Bosentan—Leukopenia—Cisplatin—esophageal cancer	0.00135	0.00238	CcSEcCtD
Bosentan—Hepatobiliary disease—Capecitabine—esophageal cancer	0.00134	0.00237	CcSEcCtD
Bosentan—Epistaxis—Capecitabine—esophageal cancer	0.00134	0.00237	CcSEcCtD
Bosentan—Irritability—Methotrexate—esophageal cancer	0.00131	0.00231	CcSEcCtD
Bosentan—Mood swings—Methotrexate—esophageal cancer	0.0013	0.00229	CcSEcCtD
Bosentan—Bradycardia—Capecitabine—esophageal cancer	0.0013	0.00229	CcSEcCtD
Bosentan—Haemoglobin—Capecitabine—esophageal cancer	0.00128	0.00226	CcSEcCtD
Bosentan—Anxiety—Cisplatin—esophageal cancer	0.00128	0.00226	CcSEcCtD
Bosentan—Haemorrhage—Capecitabine—esophageal cancer	0.00127	0.00225	CcSEcCtD
Bosentan—Hepatitis—Capecitabine—esophageal cancer	0.00127	0.00225	CcSEcCtD
Bosentan—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.00127	0.00225	CcSEcCtD
Bosentan—Hypoaesthesia—Capecitabine—esophageal cancer	0.00127	0.00224	CcSEcCtD
Bosentan—Liver function test abnormal—Methotrexate—esophageal cancer	0.00127	0.00224	CcSEcCtD
Bosentan—Discomfort—Cisplatin—esophageal cancer	0.00127	0.00224	CcSEcCtD
Bosentan—Urinary tract disorder—Capecitabine—esophageal cancer	0.00126	0.00222	CcSEcCtD
Bosentan—Oedema peripheral—Capecitabine—esophageal cancer	0.00126	0.00222	CcSEcCtD
Bosentan—Urethral disorder—Capecitabine—esophageal cancer	0.00125	0.00221	CcSEcCtD
Bosentan—Anaphylactic shock—Cisplatin—esophageal cancer	0.00123	0.00217	CcSEcCtD
Bosentan—Oedema—Cisplatin—esophageal cancer	0.00123	0.00217	CcSEcCtD
Bosentan—Infection—Cisplatin—esophageal cancer	0.00122	0.00216	CcSEcCtD
Bosentan—Erythema multiforme—Capecitabine—esophageal cancer	0.0012	0.00213	CcSEcCtD
Bosentan—Nervous system disorder—Cisplatin—esophageal cancer	0.0012	0.00213	CcSEcCtD
Bosentan—Thrombocytopenia—Cisplatin—esophageal cancer	0.0012	0.00212	CcSEcCtD
Bosentan—Tachycardia—Cisplatin—esophageal cancer	0.0012	0.00212	CcSEcCtD
Bosentan—Skin disorder—Cisplatin—esophageal cancer	0.00119	0.00211	CcSEcCtD
Bosentan—Eye disorder—Capecitabine—esophageal cancer	0.00119	0.0021	CcSEcCtD
Bosentan—Tinnitus—Capecitabine—esophageal cancer	0.00119	0.0021	CcSEcCtD
Bosentan—Hyperhidrosis—Cisplatin—esophageal cancer	0.00119	0.0021	CcSEcCtD
Bosentan—Asthma—Methotrexate—esophageal cancer	0.00118	0.00209	CcSEcCtD
Bosentan—Cardiac disorder—Capecitabine—esophageal cancer	0.00118	0.00209	CcSEcCtD
Bosentan—Flushing—Capecitabine—esophageal cancer	0.00118	0.00209	CcSEcCtD
Bosentan—Eosinophilia—Methotrexate—esophageal cancer	0.00117	0.00207	CcSEcCtD
Bosentan—Anorexia—Cisplatin—esophageal cancer	0.00117	0.00207	CcSEcCtD
Bosentan—Angiopathy—Capecitabine—esophageal cancer	0.00116	0.00204	CcSEcCtD
Bosentan—Immune system disorder—Capecitabine—esophageal cancer	0.00115	0.00203	CcSEcCtD
Bosentan—Mediastinal disorder—Capecitabine—esophageal cancer	0.00115	0.00203	CcSEcCtD
Bosentan—Hypotension—Cisplatin—esophageal cancer	0.00115	0.00203	CcSEcCtD
Bosentan—Chills—Capecitabine—esophageal cancer	0.00114	0.00202	CcSEcCtD
Bosentan—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00112	0.00198	CcSEcCtD
Bosentan—Mental disorder—Capecitabine—esophageal cancer	0.00112	0.00197	CcSEcCtD
Bosentan—Erythema—Capecitabine—esophageal cancer	0.00111	0.00196	CcSEcCtD
Bosentan—Malnutrition—Capecitabine—esophageal cancer	0.00111	0.00196	CcSEcCtD
Bosentan—Dysuria—Methotrexate—esophageal cancer	0.00111	0.00196	CcSEcCtD
Bosentan—Neutropenia—Methotrexate—esophageal cancer	0.00111	0.00196	CcSEcCtD
Bosentan—Paraesthesia—Cisplatin—esophageal cancer	0.0011	0.00195	CcSEcCtD
Bosentan—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.0011	0.00195	CcSEcCtD
Bosentan—Dyspnoea—Cisplatin—esophageal cancer	0.00109	0.00193	CcSEcCtD
Bosentan—Flatulence—Capecitabine—esophageal cancer	0.00109	0.00193	CcSEcCtD
Bosentan—Back pain—Capecitabine—esophageal cancer	0.00107	0.0019	CcSEcCtD
Bosentan—Decreased appetite—Cisplatin—esophageal cancer	0.00107	0.00189	CcSEcCtD
Bosentan—Muscle spasms—Capecitabine—esophageal cancer	0.00107	0.00188	CcSEcCtD
Bosentan—Pneumonia—Methotrexate—esophageal cancer	0.00106	0.00188	CcSEcCtD
Bosentan—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00106	0.00187	CcSEcCtD
Bosentan—Infestation—Methotrexate—esophageal cancer	0.00106	0.00187	CcSEcCtD
Bosentan—Infestation NOS—Methotrexate—esophageal cancer	0.00106	0.00187	CcSEcCtD
Bosentan—Pain—Cisplatin—esophageal cancer	0.00105	0.00186	CcSEcCtD
Bosentan—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	0.00105	0.00185	CcSEcCtD
Bosentan—Vision blurred—Capecitabine—esophageal cancer	0.00105	0.00185	CcSEcCtD
Bosentan—Tremor—Capecitabine—esophageal cancer	0.00104	0.00184	CcSEcCtD
Bosentan—Renal failure—Methotrexate—esophageal cancer	0.00104	0.00183	CcSEcCtD
Bosentan—Stomatitis—Methotrexate—esophageal cancer	0.00103	0.00182	CcSEcCtD
Bosentan—Conjunctivitis—Methotrexate—esophageal cancer	0.00103	0.00181	CcSEcCtD
Bosentan—Anaemia—Capecitabine—esophageal cancer	0.00103	0.00181	CcSEcCtD
Bosentan—Haematuria—Methotrexate—esophageal cancer	0.00101	0.00178	CcSEcCtD
Bosentan—Hepatobiliary disease—Methotrexate—esophageal cancer	0.000999	0.00177	CcSEcCtD
Bosentan—Epistaxis—Methotrexate—esophageal cancer	0.000997	0.00176	CcSEcCtD
Bosentan—Vertigo—Capecitabine—esophageal cancer	0.000996	0.00176	CcSEcCtD
Bosentan—Syncope—Capecitabine—esophageal cancer	0.000995	0.00176	CcSEcCtD
Bosentan—Leukopenia—Capecitabine—esophageal cancer	0.000993	0.00175	CcSEcCtD
Bosentan—Palpitations—Capecitabine—esophageal cancer	0.00098	0.00173	CcSEcCtD
Bosentan—Loss of consciousness—Capecitabine—esophageal cancer	0.000975	0.00172	CcSEcCtD
Bosentan—Body temperature increased—Cisplatin—esophageal cancer	0.000971	0.00171	CcSEcCtD
Bosentan—Cough—Capecitabine—esophageal cancer	0.000968	0.00171	CcSEcCtD
Bosentan—Haemoglobin—Methotrexate—esophageal cancer	0.000953	0.00168	CcSEcCtD
Bosentan—Haemorrhage—Methotrexate—esophageal cancer	0.000948	0.00168	CcSEcCtD
Bosentan—Hepatitis—Methotrexate—esophageal cancer	0.000948	0.00168	CcSEcCtD
Bosentan—Chest pain—Capecitabine—esophageal cancer	0.000944	0.00167	CcSEcCtD
Bosentan—Arthralgia—Capecitabine—esophageal cancer	0.000944	0.00167	CcSEcCtD
Bosentan—Anxiety—Capecitabine—esophageal cancer	0.000941	0.00166	CcSEcCtD
Bosentan—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000938	0.00166	CcSEcCtD
Bosentan—Urinary tract disorder—Methotrexate—esophageal cancer	0.000937	0.00165	CcSEcCtD
Bosentan—Discomfort—Capecitabine—esophageal cancer	0.000933	0.00165	CcSEcCtD
Bosentan—Urethral disorder—Methotrexate—esophageal cancer	0.00093	0.00164	CcSEcCtD
Bosentan—Dry mouth—Capecitabine—esophageal cancer	0.000923	0.00163	CcSEcCtD
Bosentan—Oedema—Capecitabine—esophageal cancer	0.000905	0.0016	CcSEcCtD
Bosentan—Hypersensitivity—Cisplatin—esophageal cancer	0.000905	0.0016	CcSEcCtD
Bosentan—Infection—Capecitabine—esophageal cancer	0.000899	0.00159	CcSEcCtD
Bosentan—Erythema multiforme—Methotrexate—esophageal cancer	0.000897	0.00158	CcSEcCtD
Bosentan—Shock—Capecitabine—esophageal cancer	0.000891	0.00157	CcSEcCtD
Bosentan—Nervous system disorder—Capecitabine—esophageal cancer	0.000888	0.00157	CcSEcCtD
Bosentan—Eye disorder—Methotrexate—esophageal cancer	0.000886	0.00157	CcSEcCtD
Bosentan—Thrombocytopenia—Capecitabine—esophageal cancer	0.000886	0.00157	CcSEcCtD
Bosentan—Tinnitus—Methotrexate—esophageal cancer	0.000884	0.00156	CcSEcCtD
Bosentan—Tachycardia—Capecitabine—esophageal cancer	0.000883	0.00156	CcSEcCtD
Bosentan—Asthenia—Cisplatin—esophageal cancer	0.000881	0.00156	CcSEcCtD
Bosentan—Cardiac disorder—Methotrexate—esophageal cancer	0.00088	0.00156	CcSEcCtD
Bosentan—Skin disorder—Capecitabine—esophageal cancer	0.000879	0.00155	CcSEcCtD
Bosentan—Hyperhidrosis—Capecitabine—esophageal cancer	0.000875	0.00155	CcSEcCtD
Bosentan—Anorexia—Capecitabine—esophageal cancer	0.000863	0.00152	CcSEcCtD
Bosentan—Angiopathy—Methotrexate—esophageal cancer	0.000861	0.00152	CcSEcCtD
Bosentan—Immune system disorder—Methotrexate—esophageal cancer	0.000857	0.00151	CcSEcCtD
Bosentan—Mediastinal disorder—Methotrexate—esophageal cancer	0.000855	0.00151	CcSEcCtD
Bosentan—Chills—Methotrexate—esophageal cancer	0.000851	0.0015	CcSEcCtD
Bosentan—Hypotension—Capecitabine—esophageal cancer	0.000846	0.00149	CcSEcCtD
Bosentan—Diarrhoea—Cisplatin—esophageal cancer	0.00084	0.00148	CcSEcCtD
Bosentan—Mental disorder—Methotrexate—esophageal cancer	0.000831	0.00147	CcSEcCtD
Bosentan—Erythema—Methotrexate—esophageal cancer	0.000826	0.00146	CcSEcCtD
Bosentan—Malnutrition—Methotrexate—esophageal cancer	0.000826	0.00146	CcSEcCtD
Bosentan—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000825	0.00146	CcSEcCtD
Bosentan—Insomnia—Capecitabine—esophageal cancer	0.000819	0.00145	CcSEcCtD
Bosentan—Paraesthesia—Capecitabine—esophageal cancer	0.000813	0.00144	CcSEcCtD
Bosentan—Dyspnoea—Capecitabine—esophageal cancer	0.000807	0.00143	CcSEcCtD
Bosentan—Back pain—Methotrexate—esophageal cancer	0.000799	0.00141	CcSEcCtD
Bosentan—Dyspepsia—Capecitabine—esophageal cancer	0.000797	0.00141	CcSEcCtD
Bosentan—Decreased appetite—Capecitabine—esophageal cancer	0.000787	0.00139	CcSEcCtD
Bosentan—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000781	0.00138	CcSEcCtD
Bosentan—Vomiting—Cisplatin—esophageal cancer	0.000781	0.00138	CcSEcCtD
Bosentan—Fatigue—Capecitabine—esophageal cancer	0.00078	0.00138	CcSEcCtD
Bosentan—Vision blurred—Methotrexate—esophageal cancer	0.000778	0.00137	CcSEcCtD
Bosentan—Rash—Cisplatin—esophageal cancer	0.000774	0.00137	CcSEcCtD
Bosentan—Pain—Capecitabine—esophageal cancer	0.000774	0.00137	CcSEcCtD
Bosentan—Constipation—Capecitabine—esophageal cancer	0.000774	0.00137	CcSEcCtD
Bosentan—Dermatitis—Cisplatin—esophageal cancer	0.000774	0.00137	CcSEcCtD
Bosentan—Anaemia—Methotrexate—esophageal cancer	0.000763	0.00135	CcSEcCtD
Bosentan—Vertigo—Methotrexate—esophageal cancer	0.000742	0.00131	CcSEcCtD
Bosentan—Gastrointestinal pain—Capecitabine—esophageal cancer	0.00074	0.00131	CcSEcCtD
Bosentan—Leukopenia—Methotrexate—esophageal cancer	0.000739	0.00131	CcSEcCtD
Bosentan—Nausea—Cisplatin—esophageal cancer	0.000729	0.00129	CcSEcCtD
Bosentan—Cough—Methotrexate—esophageal cancer	0.00072	0.00127	CcSEcCtD
Bosentan—Urticaria—Capecitabine—esophageal cancer	0.000719	0.00127	CcSEcCtD
Bosentan—Body temperature increased—Capecitabine—esophageal cancer	0.000716	0.00126	CcSEcCtD
Bosentan—Abdominal pain—Capecitabine—esophageal cancer	0.000716	0.00126	CcSEcCtD
Bosentan—EDNRB—bronchus—esophageal cancer	0.000714	0.18	CbGeAlD
Bosentan—Arthralgia—Methotrexate—esophageal cancer	0.000703	0.00124	CcSEcCtD
Bosentan—Chest pain—Methotrexate—esophageal cancer	0.000703	0.00124	CcSEcCtD
Bosentan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000698	0.00123	CcSEcCtD
Bosentan—Discomfort—Methotrexate—esophageal cancer	0.000694	0.00123	CcSEcCtD
Bosentan—Anaphylactic shock—Methotrexate—esophageal cancer	0.000674	0.00119	CcSEcCtD
Bosentan—Infection—Methotrexate—esophageal cancer	0.000669	0.00118	CcSEcCtD
Bosentan—Hypersensitivity—Capecitabine—esophageal cancer	0.000667	0.00118	CcSEcCtD
Bosentan—Nervous system disorder—Methotrexate—esophageal cancer	0.000661	0.00117	CcSEcCtD
Bosentan—Thrombocytopenia—Methotrexate—esophageal cancer	0.00066	0.00117	CcSEcCtD
Bosentan—Skin disorder—Methotrexate—esophageal cancer	0.000655	0.00116	CcSEcCtD
Bosentan—Hyperhidrosis—Methotrexate—esophageal cancer	0.000651	0.00115	CcSEcCtD
Bosentan—Asthenia—Capecitabine—esophageal cancer	0.000649	0.00115	CcSEcCtD
Bosentan—Anorexia—Methotrexate—esophageal cancer	0.000642	0.00113	CcSEcCtD
Bosentan—Pruritus—Capecitabine—esophageal cancer	0.00064	0.00113	CcSEcCtD
Bosentan—Hypotension—Methotrexate—esophageal cancer	0.00063	0.00111	CcSEcCtD
Bosentan—Diarrhoea—Capecitabine—esophageal cancer	0.000619	0.00109	CcSEcCtD
Bosentan—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000614	0.00108	CcSEcCtD
Bosentan—Insomnia—Methotrexate—esophageal cancer	0.000609	0.00108	CcSEcCtD
Bosentan—Paraesthesia—Methotrexate—esophageal cancer	0.000605	0.00107	CcSEcCtD
Bosentan—Dyspnoea—Methotrexate—esophageal cancer	0.000601	0.00106	CcSEcCtD
Bosentan—Somnolence—Methotrexate—esophageal cancer	0.000599	0.00106	CcSEcCtD
Bosentan—Dizziness—Capecitabine—esophageal cancer	0.000599	0.00106	CcSEcCtD
Bosentan—Dyspepsia—Methotrexate—esophageal cancer	0.000593	0.00105	CcSEcCtD
Bosentan—EDNRB—Signaling by GPCR—ANXA1—esophageal cancer	0.00059	0.00162	CbGpPWpGaD
Bosentan—EDNRA—bronchus—esophageal cancer	0.00059	0.149	CbGeAlD
Bosentan—Decreased appetite—Methotrexate—esophageal cancer	0.000586	0.00103	CcSEcCtD
Bosentan—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000582	0.00103	CcSEcCtD
Bosentan—Fatigue—Methotrexate—esophageal cancer	0.000581	0.00103	CcSEcCtD
Bosentan—CYP3A4—Tryptophan metabolism—CYP19A1—esophageal cancer	0.00058	0.00159	CbGpPWpGaD
Bosentan—Pain—Methotrexate—esophageal cancer	0.000576	0.00102	CcSEcCtD
Bosentan—CYP2C9—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.000576	0.00158	CbGpPWpGaD
Bosentan—Vomiting—Capecitabine—esophageal cancer	0.000576	0.00102	CcSEcCtD
Bosentan—EDNRB—Signaling by GPCR—SST—esophageal cancer	0.000574	0.00157	CbGpPWpGaD
Bosentan—Rash—Capecitabine—esophageal cancer	0.000571	0.00101	CcSEcCtD
Bosentan—Dermatitis—Capecitabine—esophageal cancer	0.00057	0.00101	CcSEcCtD
Bosentan—EDNRA—GPCR downstream signaling—GNG7—esophageal cancer	0.000568	0.00155	CbGpPWpGaD
Bosentan—Headache—Capecitabine—esophageal cancer	0.000567	0.001	CcSEcCtD
Bosentan—CYP2C9—Biological oxidations—CYP26A1—esophageal cancer	0.000567	0.00155	CbGpPWpGaD
Bosentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—esophageal cancer	0.000565	0.00155	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—GHRL—esophageal cancer	0.000559	0.00153	CbGpPWpGaD
Bosentan—CYP2C9—Metapathway biotransformation—CYP26A1—esophageal cancer	0.000559	0.00153	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—PFN1—esophageal cancer	0.000557	0.00153	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	0.000554	0.00152	CbGpPWpGaD
Bosentan—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000551	0.000973	CcSEcCtD
Bosentan—EDNRB—G alpha (q) signalling events—PIK3CA—esophageal cancer	0.000548	0.0015	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—ADCYAP1—esophageal cancer	0.000543	0.00149	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—PDE4D—esophageal cancer	0.000542	0.00148	CbGpPWpGaD
Bosentan—Nausea—Capecitabine—esophageal cancer	0.000538	0.00095	CcSEcCtD
Bosentan—Urticaria—Methotrexate—esophageal cancer	0.000535	0.000946	CcSEcCtD
Bosentan—CYP3A4—Phase 1 - Functionalization of compounds—ALDH2—esophageal cancer	0.000533	0.00146	CbGpPWpGaD
Bosentan—Abdominal pain—Methotrexate—esophageal cancer	0.000533	0.000941	CcSEcCtD
Bosentan—Body temperature increased—Methotrexate—esophageal cancer	0.000533	0.000941	CcSEcCtD
Bosentan—EDNRA—trachea—esophageal cancer	0.00053	0.134	CbGeAlD
Bosentan—CYP2C9—Biological oxidations—GSTO1—esophageal cancer	0.000527	0.00144	CbGpPWpGaD
Bosentan—CYP2C9—Metapathway biotransformation—GSTO1—esophageal cancer	0.000519	0.00142	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—GNG7—esophageal cancer	0.000516	0.00141	CbGpPWpGaD
Bosentan—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	0.000501	0.00137	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—ELMO1—esophageal cancer	0.0005	0.00137	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—CXCL2—esophageal cancer	0.0005	0.00137	CbGpPWpGaD
Bosentan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—esophageal cancer	0.000498	0.00136	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—WWOX—esophageal cancer	0.000497	0.00136	CbGpPWpGaD
Bosentan—Hypersensitivity—Methotrexate—esophageal cancer	0.000496	0.000877	CcSEcCtD
Bosentan—ABCB11—Metabolism—BLVRB—esophageal cancer	0.000492	0.00135	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—SLC52A3—esophageal cancer	0.000492	0.00135	CbGpPWpGaD
Bosentan—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	0.000492	0.00135	CbGpPWpGaD
Bosentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—esophageal cancer	0.00049	0.00134	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—AKAP13—esophageal cancer	0.000489	0.00134	CbGpPWpGaD
Bosentan—Asthenia—Methotrexate—esophageal cancer	0.000483	0.000854	CcSEcCtD
Bosentan—Pruritus—Methotrexate—esophageal cancer	0.000477	0.000842	CcSEcCtD
Bosentan—CYP3A4—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.000475	0.0013	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—FKBP1A—esophageal cancer	0.000473	0.00129	CbGpPWpGaD
Bosentan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.000469	0.00128	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—ANXA1—esophageal cancer	0.000465	0.00127	CbGpPWpGaD
Bosentan—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.000462	0.00127	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—WIF1—esophageal cancer	0.000462	0.00126	CbGpPWpGaD
Bosentan—Diarrhoea—Methotrexate—esophageal cancer	0.000461	0.000815	CcSEcCtD
Bosentan—EDNRB—lung—esophageal cancer	0.00046	0.116	CbGeAlD
Bosentan—CYP3A4—Biological oxidations—ADH7—esophageal cancer	0.000458	0.00126	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—CXCL2—esophageal cancer	0.000454	0.00124	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—SST—esophageal cancer	0.000452	0.00124	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000451	0.00124	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—PDE4D—esophageal cancer	0.000447	0.00123	CbGpPWpGaD
Bosentan—Dizziness—Methotrexate—esophageal cancer	0.000446	0.000787	CcSEcCtD
Bosentan—ABCB11—digestive system—esophageal cancer	0.000445	0.112	CbGeAlD
Bosentan—EDNRA—GPCR downstream signaling—GHRL—esophageal cancer	0.000441	0.00121	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	0.00044	0.00121	CbGpPWpGaD
Bosentan—CYP2C9—Biological oxidations—ALDH2—esophageal cancer	0.000429	0.00118	CbGpPWpGaD
Bosentan—Vomiting—Methotrexate—esophageal cancer	0.000428	0.000757	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—CSNK1A1—esophageal cancer	0.000426	0.00117	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—GNG7—esophageal cancer	0.000426	0.00117	CbGpPWpGaD
Bosentan—Rash—Methotrexate—esophageal cancer	0.000425	0.000751	CcSEcCtD
Bosentan—Dermatitis—Methotrexate—esophageal cancer	0.000424	0.00075	CcSEcCtD
Bosentan—EDNRA—Signaling by GPCR—ANXA1—esophageal cancer	0.000422	0.00116	CbGpPWpGaD
Bosentan—Headache—Methotrexate—esophageal cancer	0.000422	0.000746	CcSEcCtD
Bosentan—ABCB11—Metabolism—SLC10A2—esophageal cancer	0.000419	0.00115	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—CA1—esophageal cancer	0.000419	0.00115	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—SST—esophageal cancer	0.000411	0.00112	CbGpPWpGaD
Bosentan—CYP2C9—Biological oxidations—GSTT1—esophageal cancer	0.000408	0.00112	CbGpPWpGaD
Bosentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—esophageal cancer	0.000404	0.00111	CbGpPWpGaD
Bosentan—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.000404	0.00111	CbGpPWpGaD
Bosentan—CYP2C9—Biological oxidations—CYP2A6—esophageal cancer	0.000404	0.00111	CbGpPWpGaD
Bosentan—CYP3A4—Biological oxidations—ADH1B—esophageal cancer	0.000402	0.0011	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—GHRL—esophageal cancer	0.0004	0.0011	CbGpPWpGaD
Bosentan—Nausea—Methotrexate—esophageal cancer	0.0004	0.000707	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—XIAP—esophageal cancer	0.000399	0.00109	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—PFN1—esophageal cancer	0.000399	0.00109	CbGpPWpGaD
Bosentan—CYP2C9—Arachidonic acid metabolism—PTGS2—esophageal cancer	0.000394	0.00108	CbGpPWpGaD
Bosentan—EDNRA—G alpha (q) signalling events—PIK3CA—esophageal cancer	0.000392	0.00107	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—CA2—esophageal cancer	0.000383	0.00105	CbGpPWpGaD
Bosentan—CYP2C9—Biological oxidations—PTGS1—esophageal cancer	0.000383	0.00105	CbGpPWpGaD
Bosentan—EDNRA—lung—esophageal cancer	0.000381	0.0961	CbGeAlD
Bosentan—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.00038	0.00104	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—CTNNA1—esophageal cancer	0.000377	0.00103	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—CXCL2—esophageal cancer	0.000375	0.00103	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	0.000374	0.00102	CbGpPWpGaD
Bosentan—CYP3A4—Biological oxidations—CYP26A1—esophageal cancer	0.000374	0.00102	CbGpPWpGaD
Bosentan—CYP3A4—Metapathway biotransformation—CYP26A1—esophageal cancer	0.000369	0.00101	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—ELMO1—esophageal cancer	0.000358	0.000981	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—PLCE1—esophageal cancer	0.000356	0.000975	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—ADH7—esophageal cancer	0.000356	0.000975	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	0.000352	0.000964	CbGpPWpGaD
Bosentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—esophageal cancer	0.000351	0.000961	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—PSME1—esophageal cancer	0.00035	0.000959	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—PSME2—esophageal cancer	0.00035	0.000959	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—AKAP13—esophageal cancer	0.00035	0.000959	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—ANXA1—esophageal cancer	0.000349	0.000954	CbGpPWpGaD
Bosentan—CYP3A4—Biological oxidations—GSTO1—esophageal cancer	0.000347	0.000951	CbGpPWpGaD
Bosentan—CYP3A4—Metapathway biotransformation—GSTO1—esophageal cancer	0.000343	0.000938	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—SST—esophageal cancer	0.000339	0.000928	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—GHRL—esophageal cancer	0.00033	0.000905	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—NOTCH3—esophageal cancer	0.00033	0.000905	CbGpPWpGaD
Bosentan—CYP2C9—Biological oxidations—CYP1B1—esophageal cancer	0.000325	0.000891	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—FBXW7—esophageal cancer	0.000325	0.00089	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000323	0.000885	CbGpPWpGaD
Bosentan—CYP2C9—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000321	0.000879	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—PDE4D—esophageal cancer	0.00032	0.000877	CbGpPWpGaD
Bosentan—EDNRB—lymph node—esophageal cancer	0.000315	0.0795	CbGeAlD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	0.000314	0.00086	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—ADH1B—esophageal cancer	0.000312	0.000855	CbGpPWpGaD
Bosentan—CYP2C9—Biological oxidations—CYP19A1—esophageal cancer	0.000306	0.000838	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—GNG7—esophageal cancer	0.000305	0.000834	CbGpPWpGaD
Bosentan—CYP2C9—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000302	0.000826	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—TYMP—esophageal cancer	0.000298	0.000817	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—NOTCH2—esophageal cancer	0.000296	0.000812	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—CYP26A1—esophageal cancer	0.00029	0.000795	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—XIAP—esophageal cancer	0.000285	0.000781	CbGpPWpGaD
Bosentan—CYP3A4—Biological oxidations—ALDH2—esophageal cancer	0.000283	0.000775	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—ALOX15—esophageal cancer	0.000283	0.000774	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CTNNA1—esophageal cancer	0.00027	0.000739	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—TPI1—esophageal cancer	0.00027	0.000739	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—GSTO1—esophageal cancer	0.00027	0.000739	CbGpPWpGaD
Bosentan—CYP3A4—Biological oxidations—GSTT1—esophageal cancer	0.000269	0.000738	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CXCL2—esophageal cancer	0.000268	0.000735	CbGpPWpGaD
Bosentan—CYP3A4—Biological oxidations—CYP2A6—esophageal cancer	0.000266	0.000729	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—TGFBR2—esophageal cancer	0.000263	0.00072	CbGpPWpGaD
Bosentan—EDNRA—lymph node—esophageal cancer	0.00026	0.0657	CbGeAlD
Bosentan—ABCB11—Metabolism—ALDOB—esophageal cancer	0.000259	0.000708	CbGpPWpGaD
Bosentan—CYP3A4—Biological oxidations—PTGS1—esophageal cancer	0.000252	0.000691	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—PSME2—esophageal cancer	0.000251	0.000686	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—PSME1—esophageal cancer	0.000251	0.000686	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—ANXA1—esophageal cancer	0.000249	0.000683	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—GAPDH—esophageal cancer	0.000249	0.000682	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—SMAD4—esophageal cancer	0.000249	0.000681	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—CRABP1—esophageal cancer	0.000247	0.000676	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—SST—esophageal cancer	0.000243	0.000664	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—NOTCH3—esophageal cancer	0.000236	0.000648	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—GHRL—esophageal cancer	0.000236	0.000648	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—GNG7—esophageal cancer	0.000235	0.000643	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—FBXW7—esophageal cancer	0.000233	0.000637	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—ALDH2—esophageal cancer	0.00022	0.000602	CbGpPWpGaD
Bosentan—CYP3A4—Biological oxidations—CYP1B1—esophageal cancer	0.000215	0.000588	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—NOTCH2—esophageal cancer	0.000212	0.000581	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	0.000212	0.000581	CbGpPWpGaD
Bosentan—CYP3A4—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000212	0.00058	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—GSTT1—esophageal cancer	0.000209	0.000573	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—CYP2A6—esophageal cancer	0.000207	0.000566	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	0.000206	0.000564	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—HIF1A—esophageal cancer	0.000204	0.000558	CbGpPWpGaD
Bosentan—CYP3A4—Biological oxidations—CYP19A1—esophageal cancer	0.000202	0.000553	CbGpPWpGaD
Bosentan—CYP3A4—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000199	0.000545	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—ENO1—esophageal cancer	0.000196	0.000537	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—PTGS1—esophageal cancer	0.000196	0.000537	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—KDR—esophageal cancer	0.000195	0.000533	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—PSME1—esophageal cancer	0.000193	0.000529	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—PSME2—esophageal cancer	0.000193	0.000529	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—TGFBR2—esophageal cancer	0.000188	0.000515	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	0.000185	0.000507	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—NOTCH1—esophageal cancer	0.000183	0.000502	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—SMAD4—esophageal cancer	0.000178	0.000488	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	0.000169	0.000462	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—CYP1B1—esophageal cancer	0.000167	0.000456	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—CREBBP—esophageal cancer	0.000166	0.000455	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—BLVRB—esophageal cancer	0.000164	0.00045	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—SLC52A3—esophageal cancer	0.000164	0.00045	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—EGFR—esophageal cancer	0.000163	0.000448	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—CYP19A1—esophageal cancer	0.000157	0.000429	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—PIK3CA—esophageal cancer	0.000156	0.000428	CbGpPWpGaD
Bosentan—CYP2C9—digestive system—esophageal cancer	0.000151	0.0381	CbGeAlD
Bosentan—EDNRB—Signaling Pathways—NOS3—esophageal cancer	0.000149	0.000408	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	0.000147	0.000402	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—HIF1A—esophageal cancer	0.000146	0.000399	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—HMOX1—esophageal cancer	0.000143	0.000392	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—PIK3CA—esophageal cancer	0.000142	0.000388	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	0.00014	0.000384	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—SLC10A2—esophageal cancer	0.00014	0.000383	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—CA1—esophageal cancer	0.00014	0.000383	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—KDR—esophageal cancer	0.000139	0.000382	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—ERBB2—esophageal cancer	0.000139	0.000381	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—ABCB1—esophageal cancer	0.000137	0.000376	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—NOTCH1—esophageal cancer	0.000131	0.00036	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—CA2—esophageal cancer	0.000128	0.00035	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	0.000125	0.000342	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—CCND1—esophageal cancer	0.000123	0.000337	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—CDKN1A—esophageal cancer	0.000119	0.000326	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CREBBP—esophageal cancer	0.000119	0.000326	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—ADH7—esophageal cancer	0.000119	0.000325	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PLCE1—esophageal cancer	0.000119	0.000325	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	0.000117	0.000322	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—EGFR—esophageal cancer	0.000117	0.00032	CbGpPWpGaD
Bosentan—CYP3A4—digestive system—esophageal cancer	0.000115	0.029	CbGeAlD
Bosentan—EDNRB—Signaling Pathways—EP300—esophageal cancer	0.000113	0.00031	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—PIK3CA—esophageal cancer	0.000112	0.000306	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—SLC52A3—esophageal cancer	0.000108	0.000297	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—BLVRB—esophageal cancer	0.000108	0.000297	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—NOS3—esophageal cancer	0.000107	0.000292	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—ADH1B—esophageal cancer	0.000104	0.000285	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	0.000104	0.000284	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—PIK3CA—esophageal cancer	0.000102	0.000278	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—ERBB2—esophageal cancer	9.97e-05	0.000273	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—TYMP—esophageal cancer	9.96e-05	0.000273	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—MYC—esophageal cancer	9.87e-05	0.00027	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—CYP26A1—esophageal cancer	9.69e-05	0.000265	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—EGFR—esophageal cancer	9.65e-05	0.000264	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—ALOX15—esophageal cancer	9.44e-05	0.000259	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—CA1—esophageal cancer	9.22e-05	0.000252	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—SLC10A2—esophageal cancer	9.22e-05	0.000252	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—CREBBP—esophageal cancer	9.17e-05	0.000251	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—TPI1—esophageal cancer	9.01e-05	0.000247	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—GSTO1—esophageal cancer	9.01e-05	0.000247	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CCND1—esophageal cancer	8.81e-05	0.000241	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—ALDOB—esophageal cancer	8.64e-05	0.000236	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CDKN1A—esophageal cancer	8.52e-05	0.000233	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—CA2—esophageal cancer	8.43e-05	0.000231	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—PIK3CA—esophageal cancer	8.38e-05	0.000229	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—GAPDH—esophageal cancer	8.31e-05	0.000228	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—CRABP1—esophageal cancer	8.24e-05	0.000226	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—NOS3—esophageal cancer	8.21e-05	0.000225	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—EP300—esophageal cancer	8.11e-05	0.000222	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—TP53—esophageal cancer	8.11e-05	0.000222	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—ADH7—esophageal cancer	7.84e-05	0.000215	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PLCE1—esophageal cancer	7.84e-05	0.000215	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—GNG7—esophageal cancer	7.84e-05	0.000215	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—PTGS2—esophageal cancer	7.51e-05	0.000206	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—ALDH2—esophageal cancer	7.34e-05	0.000201	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—MYC—esophageal cancer	7.06e-05	0.000193	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—GSTT1—esophageal cancer	6.98e-05	0.000191	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—EGFR—esophageal cancer	6.91e-05	0.000189	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—CYP2A6—esophageal cancer	6.9e-05	0.000189	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	6.88e-05	0.000188	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—ADH1B—esophageal cancer	6.87e-05	0.000188	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—TYMP—esophageal cancer	6.57e-05	0.00018	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PTGS1—esophageal cancer	6.54e-05	0.000179	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—ENO1—esophageal cancer	6.54e-05	0.000179	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PSME2—esophageal cancer	6.45e-05	0.000177	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PSME1—esophageal cancer	6.45e-05	0.000177	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—CYP26A1—esophageal cancer	6.39e-05	0.000175	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—EP300—esophageal cancer	6.25e-05	0.000171	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—ALOX15—esophageal cancer	6.23e-05	0.000171	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—PIK3CA—esophageal cancer	6e-05	0.000164	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—GSTO1—esophageal cancer	5.94e-05	0.000163	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—TPI1—esophageal cancer	5.94e-05	0.000163	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—TP53—esophageal cancer	5.8e-05	0.000159	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—ALDOB—esophageal cancer	5.7e-05	0.000156	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	5.63e-05	0.000154	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—CYP1B1—esophageal cancer	5.57e-05	0.000152	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—GAPDH—esophageal cancer	5.48e-05	0.00015	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—CRABP1—esophageal cancer	5.43e-05	0.000149	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—CYP19A1—esophageal cancer	5.23e-05	0.000143	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—GNG7—esophageal cancer	5.17e-05	0.000142	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—ALDH2—esophageal cancer	4.84e-05	0.000133	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—HMOX1—esophageal cancer	4.77e-05	0.000131	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	4.68e-05	0.000128	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—PIK3CA—esophageal cancer	4.62e-05	0.000127	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—GSTT1—esophageal cancer	4.61e-05	0.000126	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—ABCB1—esophageal cancer	4.58e-05	0.000125	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—CYP2A6—esophageal cancer	4.55e-05	0.000125	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PTGS1—esophageal cancer	4.32e-05	0.000118	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—ENO1—esophageal cancer	4.32e-05	0.000118	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PSME2—esophageal cancer	4.25e-05	0.000116	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PSME1—esophageal cancer	4.25e-05	0.000116	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—CYP1B1—esophageal cancer	3.67e-05	0.000101	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	3.46e-05	9.49e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—CYP19A1—esophageal cancer	3.45e-05	9.45e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—HMOX1—esophageal cancer	3.15e-05	8.62e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—CREBBP—esophageal cancer	3.06e-05	8.39e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—ABCB1—esophageal cancer	3.02e-05	8.28e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—NOS3—esophageal cancer	2.74e-05	7.51e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PTGS2—esophageal cancer	2.51e-05	6.87e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—EP300—esophageal cancer	2.09e-05	5.71e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—CREBBP—esophageal cancer	2.02e-05	5.53e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—NOS3—esophageal cancer	1.81e-05	4.95e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PTGS2—esophageal cancer	1.65e-05	4.53e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PIK3CA—esophageal cancer	1.54e-05	4.23e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—EP300—esophageal cancer	1.38e-05	3.77e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PIK3CA—esophageal cancer	1.02e-05	2.79e-05	CbGpPWpGaD
